Title: Prevalence and Determinants of Hypertension Among People Living with HIV on Antiretroviral Therapy: A Cross-Sectional Study at Mwananyamala Hospital, Tanzania.

Meshack Morice[1,2], Jacqueline Mgumia[1]

1.Department of Sociology and Anthropology, University of Dar es Salaam, Dar es Salaam, Tanzania.

2.Department of Community Medicine, Kairuki University, Dar es Salaam, Tanzania.

Corresponding Author: Meshack Morice, P.O. Box 35091, Dar es Salaam, Tanzania, Phone: +255 764 910 402, Email: meshackmorice@gmail.com.

ABSTRACT

Introduction: Hypertension is an emerging comorbidity among people living with HIV (PLHIV) on antiretroviral therapy (ART), contributing to increased cardiovascular risk. Despite increased survival rates due to ART, PLHIV face a higher risk of hypertension compared to the general population. This study investigates the prevalence, HIV-related factors, and knowledge levels of hypertension among PLHIV on ART.

Methods: A hospital-based cross-sectional study involving 296 PLHIV on ART for over six months was conducted between September 2024 and March 2025. Data were collected using structured questionnaires and patient records. Blood pressure was measured following American Heart Association standards. Logistic regression identified factors associated with hypertension at $p<0.05$.

Results: The prevalence of hypertension was 32.8%. Higher prevalence was observed among participants aged ≥55 years (56.3%), those who were physically inactive (39.1%), obese (45.8%), or had a family history of hypertension (42.9%). Knowledge of hypertension was moderate (mean 53.9%), with only 10.8% correctly identifying normal blood pressure levels. In multivariate analysis, longer duration since HIV diagnosis (1-5 years: aOR = 3.12, p = 0.003; 6-10 years: aOR = 2.74, p = 0.003) and higher CD4 counts (≥500 cells/mm3: aOR = 1.51, p = 0.029) were independently associated with greater risk of hypertension, whereas shorter ART duration (<1 year: aOR 0.12, p=0.043) was associated with lower risk.

Conclusions: Hypertension is highly prevalent among people living with HIV on ART in Tanzania, influenced by both traditional and HIV-related factors. Integrating hypertension screening and education within HIV care services is essential. Strengthening community engagement in chronic disease screening can enhance early detection, improve awareness, and promote preventive behaviours, ultimately reducing the dual burden of HIV and non-communicable diseases.

Keywords: HIV, Hypertension, Antiretroviral Therapy, Tanzania.

INTRODUCTION

Hypertension, defined as blood pressure ≥140 mmHg systolic or ≥90 mmHg diastolic or use of antihypertensive medication, is a growing public health concern globally, affecting a quarter of individuals living with HIV in the previous decade and contributing to cardiovascular diseases (CVD), stroke, heart failure, eye problems (blindness) and other health-related issues [1-5]. Among people living with HIV (PLHIV), the advent of antiretroviral therapy (ART) has transformed HIV into a manageable chronic condition, significantly improving survival rates [6,7]. However, this prolonged survival has shifted morbidity patterns from opportunistic infections to non- communicable diseases, notably hypertension [8]. Studies suggest PLHIV on ART face a higher hypertension risk than the general population, potentially due to HIV-induced inflammation, ART side effects, and traditional risk factors such as alcohol drinking and cigarrete smoking [9].

In 2020, global prevalence of hypertension among PLHIV on ART was reported to be 23.6% [1], with the prevalence in Sub-saharan Africa ranging from 6% to 53%, compared to ART-naïve individuals (2–41%) [10-11]. The development of hypertension in PLHIV is multifactorial. With traditional risk factors such as age, obesity or overweight, excessive alcohol consumption, cigarette smoking, sedentary lifestyle, and family history of hypertension having been consistently associated with increased hypertension risk [1,2,9]. These risk factors are often more prevalent or more impactful among PLHIV due to intersecting socioeconomic, behavioral, and clinical challenges. Beyond traditional risk factors, HIV-related factors have also been associated with changes in blood pressure among people living with HIV (PLHIV). These factors include CD4 cell count, duration of HIV infection, WHO clinical stage of HIV disease, and duration of antiretroviral therapy (ART) use. These blood pressure changes may result from prolonged immune activation and chronic inflammation caused by HIV, as well as ART- induced metabolic changes [9-11]. In Tanzania, where HIV prevalence declined from 7% in 2003 to 4.5% in 2021 among adults aged 15–49

[12,13], hypertension among PLHIV on ART remains understudied. A Tanzanian study reported a 25.2% prevalence among long-term ART users (≥5 years) versus 6.9% in ART-naïve patients, suggesting a potential ART-related effect [14]. However, evidence on HIV-related factors (i.e., CD4 count, ART duration,HIV staging and HIV diagnosis duration) and hypertension risk is inconsistent, with some studies finding no association [15,16], while others report strong links [14,17]. Knowledge gaps about hypertension among PLHIV further complicate prevention efforts. Limited awareness of risk factors and complications hinders behavioral interventions [18-20], yet few studies in Tanzania have assessed this. Addressing these gaps is critical, as hypertension is a primary contributor to CVD, a leading cause of morbidity in PLHIV [2,3]. This study aimed to determine the prevalence and determinants of hypertension among PLHIV on ART, examining HIV-related factors and hypertension knowledge to inform targeted interventions.

MATERIALS AND METHODS

Study Design and Setting

This quantitative, prospective cross-sectional study was conducted from September 10, 2024 to March 29, 2025 at Mwananyamala Regional Referral Hospital (MRRH), a major referral facility in Kinondoni District, Dar es Salaam, Tanzania. Established in 2004, MRRH's Care and Treatment Clinic (CTC) serves approximately 26,000 PLHIV annually, with 50–100 daily visits, making it an ideal site for studying hypertension in this population [21].

Study population

This study enrolled PLHIV aged ≥18 years, on ART for >6 months, attending the CTC during the study period. Pregnant women and those on contraceptive pills were excluded due to potential blood pressure confounding effects. Eligibility was confirmed using CTC records.

Sample size and sampling technique

The sample size was calculated using the Cochran's formula, based on a previous prevalence of 26% from prevalence from a Tanzanian study [19], with adjustments for 10% non-response rate. The final sample size was 329 participants. Simple random sampling was employed: daily CTC patient lists were generated, each patient assigned a random number, and 329 were selected using a computer-generated random number generator. Of these, 296 participated. To reduce measurement bias, blood pressure was measured by two trained nurses using calibrated sphygmomanometers following American Heart Association guidelines [22], with two readings averaged from separate occasions to enhance

accuracy. Potential recall bias in self-reported data (e.g., smoking, alcohol use, physical activity) was mitigated by structured, pretested questionnaires with clear, simple questions to improve recall accuracy.

Variables

The dependent variable was hypertension. Independent variables included HIV-related factors (duration of HIV diagnosis, CD4 count, WHO stage, ART duration) and knowledge level. Confounding variables were traditional risk factors (age, gender, smoking, alcohol use, BMI, family history, physical activity). There were no missing data for any variables analyzed, including sociodemographic characteristics, HIV-related factors, and knowledge of hypertension, as all 296 participants provided complete responses and measurements.

Data collection procedures

Data were collected through structured questionnaires administered in Swahili during one-on-one interviews in a private room post-clinic visit. Sociodemographic data (age, gender, education, occupation, smoking, alcohol use, physical activity, family history of hypertension) and hypertension knowledge were self-reported**.** A 10-question scale assessed hypertension knowledge (normal blood pressure, risk factors, complications), scored as a percentage (0–100%). Categories were: low (0–30%), moderate (40–70%), good (80–100%). This was adopted from the Hypertension Knowledge-Level Scale (HK-LS). HIV-related factors (duration of HIV diagnosis, CD4 count, WHO HIV clinical stage, ART duration) were extracted from CTC records.

Blood Pressure Measurement

Blood pressure was measured by two registered nurses using a calibrated sphygmomanometer, following American Heart Association guidelines [22]. Participants rested for 5 minutes, seated with feet flat, arm supported at heart level. Two readings, 1–2 minutes apart, were averaged from two separate occasions. Hypertension was defined as ≥140/90 mmHg or current antihypertensive use.

Anthropometric Measurement

Height and weight were measured using a Weight and Height Scale, and BMI was calculated (kg/m²) using a mobile application. BMI categories were: underweight (<18.5), normal (18.5–24.9), overweight (25–29.9), obese (≥30).

Data Validity and Reliability

A pretest with 10 PLHIV refined the questionnaire for clarity and relevance. Reliability was ensured through a Cronbach's Alpha of ≥0.70, standardized protocols, and regular equipment calibration. Data entry was double-checked.

Data Analysis

Data were analyzed using SPSS 25. Prevalence was calculated using descriptive statistics and cross-tabulations. Bivariate logistic regression assessed crude odds ratios (COR) for HIV-related factors and hypertension, followed by multivariate logistic regression for adjusted odds ratios (aOR) in variables with $p<0.2$, controlling for confounders. Significance was set at $p<0.05$. Knowledge was evaluated through frequencies and composite scores.

Ethical Consideration

Ethical clearance was obtained from the University of Dar es Salaam Research Ethics Committee (REC) with Ref.No. AB3/12(B), with permissions from regional authorities and MRRH. Written informed consent was secured, ensuring confidentiality through coded questionnaires.

RESULTS

Descriptive Characteristics

Of 296 participants, 66.6% (197) were female, and 34.8% (103) were aged 45–54 years. Most had primary education (66.9%, 198) and were business owners (48.6%, 144). Lifestyle factors included 7.8% (23) smokers, 23.6% (70) alcohol users, and 44.9% (133) physically inactive. Family history of hypertension was reported by 21.3% (63), and 58.8% (174) were overweight/obese (Table 1).

Table 1: Descriptive characteristics of the study population

	Frequency(n)	Percent (%)
Age		
18-24 years	12	4.1
25-34 years	32	10.8
35-44 years	85	28.7
45-54 years	103	34.8
55 years and above	64	21.6
Gender		
Female	197	66.6
Male	99	33.4
Level of education		
No formal education	22	7.4
Primary school	198	66.9
Secondary school	58	19.6
High school	4	1.4
College Degree	14	4.7
Occupation		
Business owner	144	48.6

Employed	46	15.5
Farmer	8	2.7
Unemployed	98	33.1
Cigarette smoker	23	7.8
Alcohol drinker	70	23.6
Physical activity level		
Moderately active	133	44.9
Not very active	133	44.9
Very active	30	10.1
Family history of HTN		
No	233	78.7
Yes	63	21.3
BMI status (kg/m$^{2)}$		
Underweight (<18.5)	15	5.1
Normal weight (18.5—24.9)	107	36.1
Overweight (25—29.9)	102	34.5
Obese (≥ 30)	72	24.3
Overall	**296**	

Prevalence of Hypertension

Hypertension prevalence was 32.8% (97/296). The prevalence was higher among participants aged ≥55 years (56.3%), those without formal education (59.1%), and unemployed individuals (41.8%). Participants who were physically inactive (39.1%), had a family history of hypertension (42.9%), or were obese (45.8%) showed a higher prevalence compared to their counterparts (Table 2)

Table 2: Sociodemographic characteristics in hypertensive and non-hypertensive

	Hypertensive n (%)	**Non hypertensive n (%)**	**Total**
Age (years)			
18-24	2(16.7)	10(83.3)	12
25-34	6(18.8)	26(81.3)	32
35-44	21(24.7)	64(75.3)	85
45-54	32(31.1)	71(68.9)	103
≥55	36(56.3)	28(43.8)	64
Gender			
Female	64(32.5)	133(67.5)	197
Male	33(33.3)	66(66.7)	99
Level of education			
No formal education	13(59.1)	9(40.9)	22
Primary school	60(30.3)	138(69.7)	198
Secondary school	18(31.0)	40(69.0)	58
High school	0(0.0)	4(100.0)	4
College degree	6(42.9)	8(57.1)	14

Occupation			
Business owner	38(26.4)	106(73.6)	144
Employed	15(32.6)	31(67.4)	46
Farmer	3(37.5)	5(62.5)	8
Unemployed	41(41.8)	57(58.2)	98
Cigarette smokers	3(13.0)	20(87.0)	23
Alcohol drinkers	25(35.7)	45(64.3)	70
Physical activity			
Not very active	52(39.1)	81(60.9)	133
Moderately active	38(28.6)	95(71.4)	133
Very active	7(23.3)	23(76.7)	30
Family history of HTN	27(42.9)	36(57.1)	63
BMI (kg/m$^{2)}$			
Underweight (<18.5)	5(33.3)	10(66.7)	15
Normal weight (18.5-24.9)	25(23.4)	82(76.6)	107
Overweight (25-29.9)	34(33.3)	68(66.7)	102
Obese (≥ 30)	33(45.8)	39(54.2)	72
TOTAL	**97(32.8)**	**199(67.2)**	**296**

HIV-related factors showed higher prevalence with longer HIV duration (6–10 years: 38.2%), advanced WHO stages (Stage 3: 35.6%), CD4 200–349 cells/mm³ (44.4%), and ART 1–5 years (36.5%) (Table 3).

Table 3: HIV-related factors associated with HTN

	Hypertensive n (%)	**Non hypertensive n (%)**	**Total**
Duration with HIV diagnosis (years)			
<1	1(5.9)	16(94.1)	17
1-5	19(36.5)	33(63.5)	52
6-10	34(38.2)	55(61.8)	89
>10	43(31.2)	95(68.8)	138
HIV clinical staging			
Stage 1	13(26.0)	37(74.0)	50
Stage 2	12(28.6)	30(71.4)	42
Stage 3	63(35.6)	114(64.4)	177
Stage 4	9(33.3)	18(66.7)	27
Current CD4 cell count (cells/mm3)			
<200	1(4.8)	20(95.2)	21
200-349	20(44.4)	25(55.6)	45
350-499	32(34.0)	62(66.0)	94
≥500	44(32.4)	92(67.6)	136
Duration of ART use (years)			

<1	1(5.9)	16(94.1)	17
1-5	19(36.5)	33(63.5)	52
>5	77(33.9)	150(66.1)	227
TOTAL	**97(32.8)**	**199(67.2)**	**296**

Association Between HIV-Related Factors and Hypertension Bivariate and Multivariate Analysis

In bivariate analysis, Longer HIV duration (1–5 years: COR 0.297, 95% CI 0.121–0.730, p=0.008; 6–10 years: COR 0.359, 95% CI 0.172–0.750, p=0.006) and higher CD4 counts (≥500 cells/mm³: COR 0.079, 95% CI 0.009–0.692, p=0.022) reduced hypertension risk. ART <1 year increased risk (COR 1.213, 95% CI 1.069–3.095, p=0.043). WHO stage showed no association (p>0.05). Adjusting for confounders in multivariate analysis, longer HIV duration increased hypertension risk (1–5 years: aOR 3.119, 95% CI 1.772-4.787, p=0.003; 6–10 years: aOR 2.738, 95% CI 1.568–3.910, p=0.003. Higher CD4counts were strongly associated (≥500 cells/mm³: aOR 11.505, 95% CI 1.287–2.853, p=0.029; 350–499 cells/mm³: aOR 2.173, 95% CI 1.389–6.670, p=0.024). ART <1 year reduced risk (aOR 0.122, 95% CI 0.016–0.935, p=0.043). (Table 4).

Table 4: Bivariate and Multivariate analysis of HIV-related factors associated with HTN

		Bivariate		**Multivariate**	
	n	**COR (95% CI)**	**P-value**	**AOR (95% CI)**	**P-value**
Duration with HIV Diagnosis (years)					
<1	17	0.194 (0.149–0.862)	0.732	1.485 (0.146–2.082)	0.738
1–5	52	0.297 (0.121–0.730)	0.008	3.119 (1.772–4.787)	0.003
6–10	89	0.359 (0.172–0.750)	0.006	2.738 (1.568–3.910)	0.003
>10	138	1		1	
HIV Clinical Staging					
Stage 1	50	2.197 (0.620–7.788)	0.223		
Stage 2	42	1.858 (0.504–6.847)	0.352		
Stage 3	177	1.331 (0.463–3.823)	0.596		
Stage 4	27	1			
Current CD4 Cell Count (cells/mm³)					
<200	21	1		1	

200–349	45	0.057 (0.006–0.532)	0.012	1.480 (0.830–3.585)	0.071
350–499	94	0.066 (0.008–0.578)	0.014	2.173 (1.389–6.670)	0.024
≥500	136	0.079 (0.009–0.692)	0.022	1.505 (1.287–2.853)	0.029
Duration of ART Use (years)					
<1	17	1.213 (1.069–3.095)	0.043	0.122 (0.016–0.935)	0.043
1–5	52	0.892 (0.476–1.670)	0.72	1.122 (0.599–2.101)	0.72
>5	227	1		1	

Knowledge of Hypertension

Knowledge was moderate (mean 53.85%), with 26.4% (78) scoring low (0–30%), 52% (154) moderate (40–70%), and 21.6% (64) good (80–100%) (Figure 1).



Figure 1: Histogram showing the distribution of hypertension knowledge scores (%)

Only 10.8% (32) knew normal blood pressure, while awareness of risk factors like exercise (90.9%, 269) and weight gain (73.0%, 216) was higher than smoking (22.6%, 67). Complications awareness ranged from 46.3% (kidney problems) to 68.6% (heart problems) (Table 5)

Table 5: Hypertension knowledge assessment parameters in PLHIV on ART

	Frequency (n)	Percentage (%)
Normal Blood pressure		
No	264	89.2
Yes	32	10.8
Cigarette smoking		
No	229	77.4
Yes	67	22.6
Alcohol drinking		
No	139	47.0
Yes	157	53.0
Weight gain		
No	80	27.0
Yes	216	73.0
Excessive salt use		
No	113	38.2
Yes	183	61.8
Physical exercise		
No	27	9.1
Yes	269	90.9
Heart problems		

DISCUSSION

This study found a 32.8% hypertension prevalence among PLHIV on ART, higher than the global average (23.6%)[1] but within Sub-Saharan African ranges (6–53%) [10,11]. Compared to Tanzanian studies (25.2% in long-term ART users [14]), our findings suggest a significant burden, aligning with Ghana (36.7%) [23] and South Africa (53%) [11], yet exceeding lower estimates from Burundi (17.4%) [24] and Kenya (16%) [16]. Traditional risk factors such as older age (>35 years), overweight/obesity, physical inactivity, and family history-mirrored prior studies [23,25], reinforcing their role in PLHIV. HIV-related factors, including longer ART duration and advanced WHO stages, also had higher prevalence, consistent with previous studies [19,23], highlighting the role of HIV in hypertension.

Longer HIV duration (1–5 and 6–10 years) significantly increased hypertension risk, supporting previous studies [24,25]. Chronic inflammation and immune dysfunction may explain this [26,27]. However, a study done in Ghana [23] found no association, possibly due to methodological differences. Higher CD4 counts (≥350 cells/mm^3) were strongly linked to hypertension, aligning with previous literature [23], but contrasting with studies reporting lower risk [11,19,28]. Immune reconstitution or lifestyle changes post-ART may contribute [29]. Shorter ART duration (<1 year) reduced risk, consistent with previous studies [17,25], suggesting prolonged ART exposure elevates hypertension

risk, possibly through drug toxicity or lipodystrophy [17]. No association with WHO stage contrasts with previous literatures [19,30], potentially due to smaller sample size or ART's mitigating effects on disease progression.

Moderate knowledge (53.85%) with significant gaps (26.4% low knowledge levels) aligns with existing literature [15,20], highlighting a need for education. Low awareness of normal blood pressure (10.8%) and smoking (22.6%) as risk factors contrasts with higher awareness of exercise (90.9%), indicating inconsistent understanding. This study's structured assessment improves on prior vague methodologies in evaluating knowledge on hypertension [19], offering a clearer picture of knowledge deficits

STRENGTHS AND LIMITATIONS

This study's strengths include standardized measurements, and comprehensive HIV-related factor analysis. However, excluding ART-naïve patients limits comparisons, and the cross-sectional design precludes causality. Unmeasured comorbidities (e.g., diabetes) and potential pre-HIV hypertension may confound results. The moderate sample size (296) may reduce power for some associations (e.g., WHO stage).

IMPLICATIONS FOR PRACTICE AND POLICY

The 32.8% prevalence and identified risk factors necessitate integrating routine blood pressure screening into HIV care, as recommended by WHO [2]. Education programs targeting knowledge gaps (e.g., normal blood pressure, smoking) could empower PLHIV to mitigate risks. Policymakers should prioritize hypertension management protocols within CTCs, emphasizing lifestyle modifications.

FUTURE RESEARCH

Longitudinal studies are needed to establish causality between HIV/ART and hypertension, including ART-naïve controls. Expanding variables (e.g., comorbidities) and determining hypertension incidence post-HIV diagnosis would enhance understanding. Larger samples could clarify inconsistent findings (e.g., WHO stage).

ACKNOWLEDGMENTS

I thank Dr. Jacqueline Mgumia for supervision, Mwananyamala Regional Referral Hospital (MRRH) staff for support, and participants for their time

FUNDING STATEMENT

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

COMPETING INTERESTS STATEMENT

The authors declare no competing interests.

CONTRIBUTOR STATEMENT

Meshack Morice conceived the study, collected and analysed data, and wrote the manuscript. Jacqueline Mgumia supervised the study design and provided critical revisions to the manuscript

REFERENCES

1.Bigna JJ, Ndoadoumgue AL, Nansseu JR, Tochie JN, Nyaga UF, Nkeck JR, et al. Global burden of hypertension among people living with HIV in the era of increased life expectancy: a systematic review and meta-analysis. *J Hypertens*. 2020;38(9):1659-68.

2.WHO.Cardiovascular diseases (CVDs). Geneva: World Health Organization; 2021. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

3. Fragkou PC, Moschopoulos CD, Dimopoulou D, Triantafyllidi H, Birmpa D, Benas D, et al. Cardiovascular disease and risk assessment in people living with HIV: current practices and novel perspectives. *Hellenic J Cardiol*. 2023;71:42-54. https://doi.org/10.1016/j.hjc.2022.12.013

4. Ntsekhe M, Baker JV. Cardiovascular disease among persons living with HIV: new insights into pathogenesis and clinical manifestations in a global context. *Circulation*. 2023;147(1):83-100.

5. WHO. Global report on hypertension: the race against a silent killer. Geneva: World Health Organization; 2023. https://reliefweb.int/report/world/global-report-hypertension-race-against-silent-killer

6. Epps PV, Kalayjian RC. Human Immunodeficiency Virus and aging in the era of effective antiretroviral therapy. *Infect Dis Clin North Am*. 2017;31(4):791-810.

7. Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV. *Circulation*. 2018;138(11):1100-12.

8. Bigna JJ, Noubiap JJ. Global burden of hypertension in people living with HIV. *BMC Med*. 2021;19(1):112.

9. Carter M. A quarter of people living with HIV have hypertension. aidsmap.com. 2020. https://www.aidsmap.com/news/jun-2020/quarter-people-living-hiv-have-hypertension

10. Masenga SK, Hamooya BM, Nzala S, Kwenda G, Heimburger DC, Mutale W, et al. Patho-immune mechanisms of hypertension in HIV: a systematic and thematic review. *Curr Hypertens Rep*. 2019;21(7):56.

11. Tsuro U, Oladimeji KE, Pulido-Estrada GA, Apalata TR. Risk factors attributable to hypertension among HIV-infected patients on antiretroviral therapy in selected rural districts of the Eastern Cape Province, South Africa.

Int J Environ Res Public Health. 2022;19(18):11196.

12. UNAIDS. Country progress report - United Republic of Tanzania, Global AIDS Monitoring. Geneva: UNAIDS; 2020. https://www.unaids.org/sites/default/files/country/documents/TZA_2020_countryreport.pdf

13. USAID. Tanzania HIV/AIDS fact sheet. Washington, DC: USAID; 2023. https://www.usaid.gov/tanzania/fact-sheet/tanzania-hivaids-fact-sheet

14. Kato I, Tumaini B, Pallangyo K. Prevalence of non-communicable diseases among individuals with HIV infection by antiretroviral therapy status in Dar es Salaam, Tanzania. *PLoS One*. 2020;15(7):e0235542.

15. Derick KI, Khan Z. Prevalence, awareness, treatment, control of hypertension, and availability of hypertension services for patients living with Human Immunodeficiency Virus (HIV) in Sub-Saharan Africa (SSA): a systematic review and meta-analysis. *Cureus*. 2023;15(4):e37422.

16. Mogaka JN, Sharma M, Temu T, Masyuko S, Kinuthia J, Osoti A, et al. Prevalence and factors associated with hypertension among adults with and without HIV in Western Kenya. *PLoS One*. 2022;17(1):e0262400.

17. Pangmekeh PJ, Awolu MM, Gustave S, Gladys T, Cumber SN. Association between highly active antiretroviral therapy (HAART) and hypertension in persons living with HIV/AIDS at the Bamenda regional hospital, Cameroon. *Pan Afr Med J*. 2019;33:87.

18. Kagaruki GB, Mayige MT, Ngadaya ES, Kilale AM, Kahwa A, Shao AF, et al. Knowledge and perception on type 2 diabetes and hypertension among HIV clients utilizing care and treatment services: a cross-sectional study from Mbeya and Dar es Salaam regions in Tanzania. *BMC Public Health*. 2018;18(1):928.

19. Trifirò S, Cavallin F, Mangi S, Mhaluka L, Maffoni S, Taddei S, et al. Hypertension in people living with HIV on combined antiretroviral therapy in rural Tanzania. *Afr Health Sci*. 2023;23(1):129-36.

20. Biraguma J, Mutimura E, Frantz JM. Knowledge about modifiable risk factors for non-communicable diseases adults living with HIV in Rwanda. *Afr Health Sci*. 2019;19(4):3181-9.

21. Mwabenga BK. Effectiveness of HIV/AIDS social support coping skill to PLWHA in Kinondoni Municipality, Dar es Salaam: a case study of Mwananyamala Hospital. [place unknown]: [publisher unknown]; 2019.

22. American Heart Association. Standards for measuring blood pressure. Dallas, TX: American Heart Association; 2018. https://www.heart.org/en/health-topics/high-blood-pressure/understanding-blood-pressure- readings

23. Nartey ET, Tetteh RA, Anto F, Sarfo B, Kudzi W, Adanu RM. Hypertension and associated factors among patients attending HIV clinic at Korle-Bu Teaching Hospital. *Ghana Med J*. 2023;57(1):19-27.

24. Harimenshi D, Niyongabo T, Preux PM, Aboyans V, Desormais I. Hypertension and associated factors in HIV-infected patients receiving antiretroviral treatment in Burundi: a cross-sectional study. *Sci Rep*. 2022;12(1):20529.

25. Melo ES, Antonini M, Costa CRB, Sorensen W, Gir E, Reis RK. Evaluation of cardiovascular risk factors in people living with HIV in São Paulo, Brazil. *J Infect Dev Ctries*. 2020;14(1):89-96.

26. Chelvanambi S. Mechanisms of HIV-Nef induced endothelial cell stress: implications of HIV-Nef protein persistence in aviremic HIV patients. Ann Arbor, MI: ProQuest; 2019. https://www.proquest.com/docview/2305768926

27. Avagimyan A, Pogosova N, Kakturskiy L, Sheibani M, Urazova O, Trofimenko A, et al. HIV-related atherosclerosis: state-of-the-art review. *Curr Probl Cardiol*. 2023;48(9):101783.

28. Uwanyirigira D, Biracyaza E, Uzabakiriho I, Omolo J, Hakizayezu F, Nzayirambaho M. Prevalence and factors associated with hypertension among HIV positive patients on antiretroviral therapy: a hospital-based cross- sectional study in Rwanda. *Vasc Health Risk Manag*. 2023;19:857-70.

29. Molopi D. The vascular and endothelial effects of HIV, antiretroviral therapy and rooibos - functional effects and mechanism. Stellenbosch: Stellenbosch University; 2022. http://hdl.handle.net/10019.1/126003

30. Kamiński M, Prymas P, Konobrodzka A, Filberek P, Sibrecht G, Sierocki W, et al. Blood pressure in relation to the World Health Organization AIDS clinical staging among adults living in rural Kenya. *HIV AIDS Rev*. 2020;19(2):93-8.